Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment
Authors:
Open Access
- 24 June 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 76 (3) , 1017-1027
Abstract
Background: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than late life psychiatric conditions. However, its utility as a proxy for neurodegeneration has not been demonstrated. Plasma neurofilament light (NfL) is a validated biomarker of axonal damage, and has been shown to associate with hallmarks of neurodegeneration. Objective: The purpose of this investigation was to identify associations between NfL rate of change and the presence of MBI symptomatology. Methods: We evaluated the association of MBI with changes in NfL in a cohort ( n = 584; MBI + n = 190, MBI– n = 394) of non-demented participants from the Alzheimer’s Disease Neuroimaging Initiative. MBI was determined by transforming Neuropsychiatric Inventory Questionnaire items using a published algorithm. Change in NfL was calculated over 2 years. Results: Time*MBI status was the only significant interaction to predict change in NfL concentrations ( F(1,574) = 4.59, p = 0.032), even after controlling for age, mild cognitive impairment, and demographics. Analyses reclassifying 64 participants with new onset MBI over 2 years similarly demonstrated greater increases in NfL ( F(1,574) = 5.82, p = 0.016). Conclusion: These findings suggest MBI is a clinical proxy of early phase neurodegeneration with putative utility in identifying those at dementia risk. MBI can be used as a case ascertainment approach to capture those at high risk for cognitive decline and dementia, and is an important construct for clinicians dealing with cognitive and neuropsychiatric symptomatology in older adults.Keywords
This publication has 52 references indexed in Scilit:
- Monoaminergic neuropathology in Alzheimer’s diseaseProgress in Neurobiology, 2017
- Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative DiseasesNeuron, 2016
- Why has therapy development for dementia failed in the last two decades?Alzheimer's & Dementia, 2015
- Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairmentAlzheimer's & Dementia, 2015
- “Noncognitive” symptoms of early Alzheimer diseaseNeurology, 2015
- Baseline Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Population-Based StudyAmerican Journal of Psychiatry, 2014
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013
- The Association of Neuropsychiatric Symptoms in MCI with Incident Dementia and Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2013
- Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control studyThe Lancet Neurology, 2012
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011